Kyverna Therapeutics, Inc.
KYTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $133 | $83 | $162 |
| - Cash | $34 | $53 | $57 | $97 |
| + Debt | $1 | $6 | $7 | $8 |
| Enterprise Value | – | $85 | $33 | $73 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | -$36 | -$42 | -$44 | -$37 |
| % Margin | – | – | – | – |
| Net Income | -$37 | -$42 | -$45 | -$37 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.85 | -0.97 | -1.03 | -0.87 |
| % Growth | 12.4% | 5.8% | -18.4% | – |
| Operating Cash Flow | -$43 | -$32 | -$45 | -$37 |
| Capital Expenditures | -$0 | -$0 | $0 | -$1 |
| Free Cash Flow | -$44 | -$32 | -$45 | -$38 |